Skip to main content
See every side of every news story
Get Started
SubscribeLogin
Published • loading... • Updated

Verastem Bets on Higher Cancer Drug Dose as It Maps Potential Approval Path

Summary by MarketBeat
Verastem (NASDAQ:VSTM) plans to advance a 900-milligram dose of its experimental KRAS G12D inhibitor VS-7375 across cancer indications, citing evidence of a dose response and a tolerability profile executives said was comparable to the 600-milligram dose. At a fireside chat, company executives disc

1 Articles

MarketBeatMarketBeat
Center

Verastem Bets on Higher Cancer Drug Dose as It Maps Potential Approval Path

Verastem (NASDAQ:VSTM) plans to advance a 900-milligram dose of its experimental KRAS G12D inhibitor VS-7375 across cancer indications, citing evidence of a dose response and a tolerability profile executives said was comparable to the 600-milligram dose. At a fireside chat, company executives disc

·Sioux Falls, United States
Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • 100% of the sources are Center
100% Center

Factuality Info Icon

To view factuality data please Upgrade to Premium

Ownership

Info Icon

To view ownership data please Upgrade to Vantage

MarketBeat broke the news in Sioux Falls, United States on Wednesday, November 11, 2026.
Too Big Arrow Icon
Sources are mostly out of (0)
Blindspot Title And Logo
Stories disproportionately reported by the Left or the Right

Similar News Topics

Needham icon

Needham

News
Feed Dots Icon
For You
Search Icon
SearchBlindspot LogoBlindspotLocal